Malika Ammam, PhD,  —

Researchers at various institutions from the African country of Cameroon recently found a link between oxidative stress and sickle cell disease (SCD). The study, “Oxidative profile of sickle cell patients in a Cameroonian urban hospital,” was published in…

A Phase 2 clinical trial, aiming to assess the effects of hydroxyurea-based therapy at the maximum tolerated dose to prevent stroke in children with sickle cell anemia (SCA), began recently, and the outcomes are expected to highly impact children worldwide, particularly those living in developing countries where the disease is…

Researchers in Brazil failed to find any genetic determinants for incidents of stroke in children with sickle cell disease (SCD), although their findings did suggest that SCD boys and those with sickle cell anemia were most at risk. The study, “Genetic determinants and stroke in children with sickle cell…

Researchers developed an evaluation method that accurately and comprehensively assesses antibiotic prophylaxis adherence in children with sickle cell disease (SCD). The study, “A validated measure of adherence to antibiotic prophylaxis in children with sickle cell disease,” was published in Patient Preference and Adherence. SCD, a genetic disorder that…

Alberta Children’s Hospital, the world’s leading pediatric center for stem cell (SC) transplant, is welcoming more sickle cell (SC) anemia patients for transplant procedures. SC anemia is a genetic disorder that alters the shape of the hemoglobin, a protein component of red blood cells responsible for transporting oxygen…

A study by researchers at the Hospital for Sick Children, Toronto reveals that the drug hydroxyurea can benefit children with sickle cell (SC) disease related lung problems. The study, “Effect of Hydroxyurea on Pulmonary Function Decline in Children with Sickle Cell Disease,” was presented at the ATS 2016 International…

A study performed by researchers at Baskent University, in Ankara, Turkey, found that mutations in certain genes play a role in the deposition of iron in the liver of patients with sickle cell (SC) disease. Findings, presented in the study “Effect of Hereditary Hemochromatosis Gene (HFE)…

Acetylon Pharmaceuticals recently published the outcomes of its preclinical data concerning the mechanism of action of its selective inhibition based treatment of sickle cell (SC) disease/beta-thalassemia (BT). These findings, “Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2,” were published in…